Mark Millich, 26 years old and insecure about his thinning hair, was curious about the ads he saw promising to reverse his ...

The minute-long ad from telehealth company Hims & Hers shows imagery including a scale, food including pies and cheeseburgers, and a refrigerator full of vials of Hims & Hers-labeled medications ...

Hims & Hers Health has undeniably captured market attention and investor enthusiasm, fueled by a successful Super Bowl ad campaign and its strategic entry into the high-demand GLP-1 weight loss ...

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site. The ad also hit a nerve with the pharma industry, lawmakers and some industry groups. The ad ...

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.

Telehealth stock Hims & Hers (HIMS) spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper GLP-1 weight-loss drugs sparked controversy. The ad criticized the American ...

Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...

Hims & Hers saw a massive YTD surge, but FDA news led to a pullback. Find out why HIMS stock is still undervalued and why ...

Hims & Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the public ...

Hims & Hers Health will shut down Apostrophe, its personalized acne treatments dermatology business, the company said on Friday. Apostrophe is being shut down to “simplify its (company’s) dermatology ...